Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:GLCCI1 polymorphism rs37973 and asthma treatment response to inhaled corticosteroids
Avtorji:ID Rijavec, Matija, Klinika Golnik (Avtor)
ID Žavbi, Mateja, Klinika Golnik (Avtor)
ID Lopert, Anton (Avtor)
ID Fležar, Matjaž, Klinika Golnik (Avtor)
ID Korošec, Peter, Klinika Golnik (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite http://www.jiaci.org/revistas/vol28issue3_3.pdf
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background. Asthma treatment response is highly variable and pharmacogenetic markers that predict treatment response would be one step closer to personalized treatment. GWAS studies have shown that polymorphisms GLCCI1 could be associated with asthma treatment response to inhaled corticosteroids (ICS). Materials and methods. We genotyped rs37973 of GLCCI1 in 208 adult asthma patients treated with ICS. Change in % predicted FEV1 was analysed after short-term (3 months) and after long-term (at least 3 years) treatment. Treatment success was defined as good when FEV1 decreased less than 30 ml/year. Results. After 3 months of treatment, change of % predicted FEV1 was higher in patients with GG genotype than in patients with AG+AA genotype, and this genotype dependent difference was only evident in non-smokers. Similar results were found after at least 3 years of treatment when all patients were analysed, in non-smokers and patients with atopy. Even though, no differences in treatment success (good vs. poor response) were observed when analysing the entire group of patients, genotype dependent treatment success was highly influenced by smoking and atopy. GG genotype was overrepresented in non-smokers and patients with atopy with good response. Conclusions. Rs37973 was associated with short- and long-term treatment response; however, there was a great influence of smoking and atopy on pharmacogenetic association. Furthermore, we found GG genotype to be associated with better treatment response, what is contrary to results found in GWAS.
Ključne besede:asthma -- diagnosis -- therapy, pharmacogenetics, genetic polymorphism, smoking, inhaled corticosteroids, atopy, GLCCI1, FEV1, rs37973
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Španija
Založnik:Esmon Publicidad
Leto izida:2018
Št. strani:str. 165-171
Številčenje:Vol. 28, iss. 3
PID:20.500.12556/DiRROS-12914 Novo okno
UDK:616.2
ISSN pri članku:1698-0808
DOI:10.18176/jiaci.0229 Novo okno
COBISS.SI-ID:2048262769 Novo okno
Avtorske pravice:© 2018 Esmon Publicidad, S.A.
Opomba:Soavtorji: Žavbi M, Lopert A, Fležar M, Korošec P; Nasl. z nasl. zaslona; Opis vira z dne 21. 3. 2018;
Datum objave v DiRROS:16.12.2020
Število ogledov:1392
Število prenosov:386
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Journal of investigational allergology & clinical immunology
Skrajšan naslov:J. investig. allergol. clin. immunol.
Založnik:Esmon Publicidad
ISSN:1698-0808
COBISS.SI-ID:524162329 Novo okno

Sekundarni jezik

Jezik:Španski jezik
Ključne besede:astma -- diagnostika -- terapija, farmakogenetika, genetski polimorfizem, kajenje, inhalacijski kortikosteroidi, atopija


Nazaj